Introduction {#S0001}
============

Recently, molecular imaging techniques have been widely developed for the diagnosis and detection of early stage tumors.[@CIT0001]--[@CIT0004] Current tumor imaging in the clinic is still largely based on anatomical imaging methods that detect potentially malignant lesions or on the detection of enhanced metabolism in activated leukocytes or cancer cells using fluorine-18-radiolabeled fluorodeoxyglucose positron emission tomography (PET).[@CIT0005] Although useful, most commonly used PET tracers do not target a specific receptor on the surface of the cells involved in the disease process. Therefore, the use of a specific targeting moiety, eg FDA-approved monoclonal antibodies (mAbs), is being studied for diagnosis and treatment of cancer. A few of the most commonly used mAbs are the human epidermal growth factor receptor 2 (HER2)-specific Trastuzumab and the anti-epidermal growth factor receptor (EGFR) mAb Cetuximab.[@CIT0006]--[@CIT0008] Recent advances have been made in targeted preclinical imaging using eg a visualizing SKOV-3 xenografts with positron emission tomography using Trastuzumab in a pretargeting approach.[@CIT0009],[@CIT0010] Even though, direct targeting of tumor-associated antigens is a potent tool, the use of a less expensive, non-radioactive and broader targeting moiety could be beneficial.

More widely available targets are for example biomarkers that are preferentially expressed on newly formed blood vessels in tumors, such as the vascular endothelial growth factor (VEGF) and the apha(v)beta(3)integrin (αvβ3). Tumor angiogenesis, or the sprouting of new vessels from preexisting vasculature, is well recognized as an essential mechanism for tumor growth and the development of metastasis.[@CIT0011],[@CIT0012] Without neoangiogenesis, tumors cannot grow beyond 1--2 mm in size as oxygen and nutrient supply will be restricted.[@CIT0013],[@CIT0014] Once vascularized, previously dormant tumors begin to grow rapidly, invade surrounding tissues (invasion), and transfer to distant sites in the body (metastasis). Among the various ligands, the integrin ligands have been widely studied. The Arg-Gly-Asp (RGD) motif and its structurally related compounds are some of the most studied integrin binding domains.[@CIT0015],[@CIT0016] The RGD motif specifically recognizes ανβ3 and ανβ5 integrins, which are overexpressed on many solid tumors and tumor vasculature, eg in human glioma.[@CIT0017]

Iron oxide (Fe~3~O~4~) nanoparticles (NPs) have been particularly well studied as magnetic resonance imaging (MRI) contrast agents because of their unique magnetic properties, high sensitivity, and low toxicity.[@CIT0018] However, traditional Fe~3~O~4~ NPs are prone to aggregation. They can easily be eliminated by macrophages after injection due to their inherent large surface energy and magnetic dipole interactions.[@CIT0019],[@CIT0020] Therefore, appropriate surface modifications or coatings are necessary to improve their colloidal stability and biocompatibility. For example, by incorporation into liposomes, a lipid coating is provided, which allows efficient and flexible functionalization of the particles.

The use of liposomes to encapsulate Fe~3~O~4~ NPs and the advantages of such systems were already described in the early nineties. Bulte et al found that when magnetic NPs were encapsulated within large unilamellar vesicles, ie magnetoliposomes (MLs), they could efficiently label human blood mononuclear cells, such as peripheral blood lymphocytes and monocytes. This increased their MR relaxivity threefold when compared to relaxivities achieved using dextran coated magnetite NPs.[@CIT0021] By directly attaching the double lipid layer to the iron oxide cores ("small MLs") their contrast properties were further improved, making them favorable for in vivo applications.[@CIT0022],[@CIT0023] MLs can easily be synthesized for modifying their surface charge, incorporate fluorescence markers or add moieties for targeting specific cell types.[@CIT0024]--[@CIT0026] Liposomes with a diameter of up to 120 nm passively accumulate in tumor tissues via the surrounding "leaky" vasculature and the enhanced permeability and retention effect.[@CIT0027],[@CIT0028] Active targeting, achieved by modifying sterically stable liposomes with mAbs, folic acid or transferrin, enhances this passive accumulation.[@CIT0029],[@CIT0030]

Coupling the liposomes to the RGD motif is a favorable strategy to achieve targeted delivery of these Fe~3~O~4~ NPs to tumors and their neovasculature and thus, for the NP-guided imaging of tumors. In the present study, our aim was to produce "small" MLs conjugated with the RGD peptide on the liposomal surface, resulting in RGD-functionalized MLs (RGD-MLs) targeting the ανβ3 integrin. Further functionalization of the MLs was achieved by incorporation of a Texas-Red fluorophore, which allowed monitoring of ML uptake by tumors using both in vivo MRI and fluorescence imaging (FLI), a fast and inexpensive imaging method. The targeting capabilities of the MLs towards tumor cells were evaluated in a preclinical SKOV-3 xenograft model for ovarian cancer.

Materials and methods {#S0002}
=====================

Synthesis and characterization of cyclic RGD-MLs (cRGD-MLS) {#S0002-S2001}
-----------------------------------------------------------

Anionic MLs were synthesized and iron and phospholipid content of the MLs was measured as previously described by De Cuyper et al.[@CIT0031] The full experimental details can be found wihin the Supplementary materials and [Figure S1](#F0001){ref-type="fig"}. The particles were characterized by fluorescence activated cell-sorting (FACS), transmission light microscopy (TEM), dynamic light scattering (DLS) and zeta potentials were determined, as described in detail in Supplementary materials.Figure 1TEM images of magnetoliposomes (MLs). (**A**) anionic MLs, (**B**) c-RGD MLs. Note the covering around the nanoparticles (phospholipidc bilayer). Scale bar (**A**) =200 nm. (**B**) =200 nm.

Cell culture {#S0002-S2002}
------------

All cells were kept in culture in a humidified incubator at 37°C, 21% O~2~ and 5% CO~2~. The cell media described below were enriched with 10% heat-inactivated fetal bovine serum, 100 U/l penicillin and 100 μg/ml streptomycin. A human ovarian cancer cell line (SKOV-3; originally acquired from ATCC (Manassas, VA, USA), reference code ATCC^®^ HTB-77™) transduced with a lentiviral vector encoding for enhanced green fluorescent protein and firefly luciferase was maintained in McCoy's 5A modified medium. A mouse hepatic stellate cell line (GRX, kindly provided by prof. Leo van Grunsven, LiVR, ULB, Brussels, Belgium, originally acquired from Cell Biologics, Catalog No. C57-6242) and a human epithelial cell line (BEAS2B, also acquired from ATCC, reference code ATCC^®^ CRL-9609™) were maintained in DMEM medium further supplemented with 1% glutamine. All cell culture components were purchased from Gibco (Life Technologies, Carlsbad, CA, USA).

High-content image analysis for assessment of cell viability, mitochondrial ROS, and morphology {#S0002-S2003}
-----------------------------------------------------------------------------------------------

High-content (HC) imaging studies were conducted as previously described.[@CIT0032] Briefly, 1.5×10^3^ cells/well were seeded in 96-well plates (Nunc^®^, Roskilde, Denmark) in 100 µL culture media and incubated *overnight* in a humidified atmosphere at 37°C with 5% CO~2~. The following day the cells were exposed to the MLs for 24h in culture medium at following concentrations: 0, 5, 10, 25, 50, 75, and 100 µg/ml. All experiments were performed in triplicates. Stainings were performed for actin, mitochondrial reactive oxygen species (ROS) and live-dead green, as described in Supplementary materials.

Animal experiments {#S0002-S2004}
------------------

Mice were kept in individual ventilated cages with *ad libitum* access to food and water. For the generation of xenografts, 1×10^7^ SKOV-3 cells resuspended in 100 µl of PBS (Gibco) were injected in the right flank of female Swiss nude mice (7--8 weeks, Charles River, Ecully, France) when anaesthetized with 2% isoflurane (IsoVET, 100 mg/g, Eurovet, Piramal, Healthcare, London, UK) in 100% O~2~. Mice were injected intravenously with 250 µL of either anionic or cRGD-MLs (corresponding to 400 µg total \[Fe\]) via the tail vein after the tumors were allowed to grow for approximately three weeks.

In all cases, animals were sacrificed with an overdose of pentobarbital (Nembutal, CEVA Santé Animale, Diegem, Belgium) and exsanguinated before the tumor, liver and spleen were harvested.

In vivo imaging {#S0002-S2005}
---------------

### MR imaging {#S0002-S2005-S3001}

All MRI measurements were performed using a 7T Bruker Biospec small-animal MR scanner (Bruker Biospin, Ettlingen, Germany) with a horizontal bore of 30 cm and equipped with actively shielded gradients (200 mT m^−1^). In vivo data was acquired using a quadrature radio-frequency resonator (transmit/receive; inner diameter 8.6 cm, Bruker Biospin). Uptake of RGD-MLs by the tumors was evaluated by using dynamic contrast enhanced (DCE) MRI (fast low angle shot sequence with repetition time (TR) =20 ms, echo time (TE) =3.27 ms, 20 repetitions, flip angle =30°, matrix =128 x 128 x 45, field of view (FOV) =40 x 40 mm^2^), T2 weighted fast spin echo MRI (rapid acquisition with refocused echoes (RARE) with TR =1751 ms, TE =28.07 ms, RARE factor =8, averages =10, matrix =192 x 256, FOV =40 x 40 mm^2^, 2 slice packages with each 7 slices of 1 mm thickness and a 1 mm slice gap) and T2 maps (multi-slice multi-echo sequence with TR =1500 ms, TE =8 ms, 8 echoes, matrix =128 x 192, FOV =40x 40 mm^2^, 2 slice packages with each 7 slices of 1 mm thickness and a 1 mm slice gap).

MRI scans were acquired immediately before and after administration of MLs, and 2, 4, 24 and 48h after the injection of either anionic or RGD-functionalized MLs. An outline of the experimental design can be found in [Figure S2](#F0002){ref-type="fig"}. The manufacturer's software Paravision 6.0.1 (Bruker Biospin, Ettligen, Germany) was used to generate the parametric T2 maps and to analyze the images. Regions of interest (ROIs) were drawn across the tumor in three adjacent slides and average T2 values were calculated. ROIs were kept equal in size across one animal.Figure 2Magnetic resonance imaging (MRI) of mice injected with magnetolipsomes (MLs) (**A**) Representative in vivo MRI (T2-weighted RARE) before and 2, 4, 24 and 48h post-injection of cRGD-MLs and anionic MLs. Red arrows point to hypointense areas of signal changes, indicating uptake of RGD-MLs. (**B**) Quantification of the T2 values based on parametric T2 maps acquired by multi slice-multi echo MRI. Significant differences were detected between animals injected with cRGD-MLs and anionic MLs. Data are presented as mean ± SD (two-way ANOVA). \*\**p*\<0.01, \*\*\**p*\<0.001, \*\*\*\**p*\<0.0001 vs baseline (n=9 animals/group).

### Fluorescence imaging {#S0002-S2005-S3002}

Tumor-bearing mice were given low fluorescent pellets (2019 Teklad Global 19% Protein Extruded Diet (Envigo, Gannat, France) starting from seven days before the onset of the experiments. In vivo and ex vivo FLI was performed using an IVIS Spectrum (Perkin Elmer, Waltham, MA, USA) with an excitation wavelength of 570 nm and emission filter of 620 nm. Signal intensities were measured before, immediately after administration and 2, 4, 24 and 48h after the intravenous administration of the particles via the tail vein ([Figure S2](#F0002){ref-type="fig"}). Three scans were acquired at each time point. After the animals were sacrificed, the tumors were removed and ex vivo FLI was performed.

To quantify the in vivo relative total radiant efficiency within the tumors, circular ROIs were drawn around the tumors, using the manufacturers Living Image software version 4.5.2 (Perkin Elmer). These ROIs were equal in size across one animal. All results were normalized to baseline.

Ex vivo confirmation of ML uptake {#S0002-S2006}
---------------------------------

### Fluorescence imaging {#S0002-S2006-S3001}

After the animals were sacrificed, ex vivo FLI was performed on the tumors, livers and spleens. Total radiant efficiency was determined by manual delineation of the organs. Total radiant efficiency of the background was also determined by use of the same ROI. Data are represented as the total radiant efficiency of the tumor region divided by that of the background (control region).

### Electron paramagnetic resonance (EPR) spectroscopy {#S0002-S2006-S3002}

After the animals were sacrificed, organs were harvested, freeze-dried and crushed into a fine powder. The dry samples were analyzed using a Bruker EMX-Plus EPR spectrometer (Bruker, Rheinstetten, Germany), operating in X-band (9.85 GHz) and equipped with a PremiumX ultra low noise microwave bridge and a SHQ high sensitivity resonator. The following settings were used: microwave power =5.05 mW, center field =3150 G, field sweep width =5000 G, modulation amplitude =30 G, time constant =20.48 ms, conversion time =20.48 ms, modulation field =100 kHz. Measurements were performed at room temperature. The iron oxide content in each freeze-dried organ was quantified using a calibration curve for different concentrations of pure MLs after water removal (heating to 60°C for 3 days). Endogenous superparamagnetic iron content was normalized to the weight of the whole dry organs of cRGD-MLs injected animals or control animals and expressed in ng Fe~3~O~4~ per mg of dry tissue.

### Histology {#S0002-S2006-S3003}

Harvested organs were fixed overnight in 4% paraformaldehyde (Acros Organics, Thermo Fisher Scientific, Geel, Belgium) and stored in 0.1% sodium azide (in PBS; Acros Organics) until further processing. Samples were embedded in paraffin and 5 µm thick sections were made using a microtome. Afterwards, sections were deparaffinized and dehydrated by passing through a graded alcohol series. Perl's staining was performed to visualize iron in the respective tissue sections. Images were acquired using the Axio Scan.Z1 (Carl Zeiss, Göttingen, Germany).

Statistical analysis {#S0002-S2007}
--------------------

Comparisons between groups were performed using Student's *t*-test or two-way ANOVA. Bonferroni and Tukey's post hoc tests were applied, respectively to determine statistical significance of treated groups relative to the control group or between two treated groups under one condition. In all figures, results are represented as means ± standard deviation (SD). Differences were considered statistically significant if *p*\<0.05.

Results {#S0003}
=======

ML characterization {#S0003-S2001}
-------------------

In-house synthetized MLs were characterized by TEM and DLS, with TEM indicating a spherical morphology of Fe~3~O~4~ particles, each individually enveloped by a phospholipid bilayer (anionic MLs -[Figure 1A](#F0001){ref-type="fig"}, cRGD-MLs -- [Figure 1B](#F0001){ref-type="fig"}). DLS analysis revealed similar hydrodynamic diameters (HD) and polydispersity indices (PDI) for anionic and cRGD-MLs. Furthermore, both types of MLs are negatively charged as indicated by zeta (Z) potential measurements ([Table 1](#T0001){ref-type="table"}). FACS analysis showed two different populations: a negative fraction (no Texas Red, with a mean fluorescence intensity of 0 and 10^2^ units, respectively) and a positive fraction corresponding to the functionalized MLs, with an increase in fluorescence intensity (10^2^--10^4^ units). The increase of fluorescence intensity of the MLs is directly proportional to the ratio of fluorescent probe used during the coupling, confirming the incorporation of the cRGD peptide with a coupling efficiency of 93.4%.Table 1Characterization of anionic and RGD-functionalized magnetoliposomes (MLs) by dynamic light scatteringHD (nm)PDIΖ-Potential**Anionic MLs**53.5±0.30.36±0.07−59.75±5.12**cRGD-MLs**57.8±3.70.32±0.03.− 65.12±2.02[^2]

No toxicity of cRGD-MLs was observed on SKOV-3 cells {#S0003-S2002}
----------------------------------------------------

BEAS-2B, GRX and SKOV-3 were exposed in vitro to anionic and cRGD-MLs with increasing concentrations of iron (5--100 µg Fe/ml medium). No significant differences were observed on viability, mitochondrial ROS formation, or cell morphology when cells were exposed to either anionic or cRGD MLs for 24 hrs ([Figure S3](#F0003){ref-type="fig"}).Figure 3Fluorescence imaging (FLI) of mice injected with magnetoliposomes (MLs). (**A**) Representative in vivo FLI images before and 2, 4, 24 and 48 h post-injection of cRGD-MLs and anionic MLs. (**B**) Quantification of the total radiant efficiency based on FLI data. There is a significant difference between cRGD-ML and anionic ML injected animals. Data are presented as mean ± SD (Two-Way ANOVA). \*\*\**p*\<0.001, \*\*\*\**p*\<0.0001 vs baseline (n=3/group, except RGD-group for FLI: n=4). (**C**) Quantification of the total radiant efficiency of tumor region ex vivo, comparing the tumor with a control region of cRGD-ML and anionic-ML injected animals 2h, 4h and 48h after injection. \**p*\<0.05 compared to 2h group (n=3 animals p/group). No results are shown for the group that received anionic MLs at 48h due to acquisition problems.

Successful follow up of cRGD-MLs uptake in SKOV-3 tumor xenografts in vivo by MRI and FLI {#S0003-S2003}
-----------------------------------------------------------------------------------------

MRI and FLI were used to determine the direct targeting capabilities of cRGD-MLs in vivo, by allowing the visualization and quantification of the MLs uptake at the tumor site of SKOV-3 xenografts longitudinally. We clearly see a decrease of signal intensity (hypointense area) in MRI after 2h (as indicated by white arrows in [Figure 2A](#F0002){ref-type="fig"}), The imaging results were confirmed by a decrease in T2 relaxation time, which is largest 4h after injection of cRGD-MLs (52.06±0.71 ms) compared to anionic MLs (63.6±1.6 ms) ([Figure 2B](#F0002){ref-type="fig"}). T2 values remained stable after 24h and 48h, showing a significant decrease in T2 relaxation time due to the presence of superparamagnetic iron oxide cores in the tumor site, accompanied by an increase of total radiant efficiency in FLI over time, with a maximum at 24h ([Figure 3A](#F0003){ref-type="fig"}).

FLI quantification confirms an increase in total radiant efficiency at the tumor site, immediately after the injection of the Texas Red-labeled cRGD-MLs, with a maximum uptake at 24h. Immediately after injection of the anionic MLs, one mouse died. The results of this animal were excluded. Four hours after injection of anionic MLs, a decrease in total radiant efficiency in the xenograft area was measured, which persisted during the whole experiment ([Figure 3B](#F0003){ref-type="fig"}). This confirms the lack of uptake of non-functionalized MLs by the tumor.

Confirmation of crgd-ml uptake in SKOV-3 tumor xenografts by ex vivo FLI and EPR spectroscopy {#S0003-S2004}
---------------------------------------------------------------------------------------------

Quantification of the ex vivo total radiant efficiency (%) of tumors of cRGD and anionic-MLs injected animals indicates a clear increase in the fluorescent intensity in the tumor of cRGD-MLs injected animals, and thus presence of particles after 2h of injection ([Figure 3C](#F0003){ref-type="fig"}).

The ex vivo FLI results are further confirmed by EPR spectroscopy. We found an increase in the total iron content in cRGD-MLs injected animals at 4h after injection (1.26±0.30 ng Fe~3~O~4~/mg dry tissue or 0,12% ±0,04 of total dose) in comparison with anionic MLs (0.39±0.03 ng Fe~3~O~4~/mg dry tissue or 0,06±0,02% of total dose; [Table 2](#T0002){ref-type="table"}) . The total superparamagnetic iron concentration is also significantly higher in the tumors of cRGD-MLs injected animals in comparison to control animals (0.37±0.02 ng Fe~3~O~4~/mg dry tissue; [Figure 4A](#F0004){ref-type="fig"}) This was also confirmed by the lower iron uptake in the liver of cRGD-MLs injected animals (72.78±0.40 ng Fe~3~O~4~/mg dry tissue) in comparison with animals injected with anionic-MLs (86.65±0.67 ng Fe~3~O~4~/mg dry tissue), due to an enhanced uptake of the NPs inside the tumor. We also observed an increased accumulation of the cRGD-MLs in the spleen (231.3±172.59 ng Fe~3~O~4~/mg dry tissue) in comparison with animals injected with anionic-MLs (57.24±43.81 ng Fe~3~O~4~/mg dry tissue; [Figure 4B](#F0004){ref-type="fig"}).Table 2MLs uptake in SKOV-3 xenografts at the different time points of the experimentTime Post MLs Injection2h4h48h**MLs Uptake (ng Fe~3~O~4~/mg tumor)** **Anionic MLs**0.58±0.380.39±0.030.60±0.38 **cRGD-MLs**0.92±0.791.26±0.300.68±0.46**% MLs Uptake** **Anionic MLs**0.08±0.060.06±0.020.04±0.03 **cRGD-MLs**0.14±0.110.12±0.040.07±0.03**Ratio Uptake %** **cRGD-MLs/Anionic MLs**1.792.031.76[^3] Figure 4Ex vivo electron paramagnetic resonance spectroscopy (EPR). (**A**) Quantification of the total iron concentration \[Fe\] in the tumor tissue by EPR spectroscopy over-time (h= hours). Data are presented as mean ± SD (two-way ANOVA), (n=3 animals p/group). (**B**) Quantification of the total iron concentration in the tumor tissue of cRGD, anionic magnetoliposomes (MLs) and control (Ctrl) animals by EPR spectroscopy, in comparison with liver and spleen (excretion route) 2h after injection of the MLs. Data are presented as mean ± SD (two-way ANOVA).

Histology {#S0003-S2005}
---------

To confirm the uptake of cRGD-MLs by the SKOV-3 xenografts tumor, tissue sections of both cRGD-MLs and anionic-MLs injected animals were stained with Perl's stain ([Figure 5](#F0005){ref-type="fig"}). No staining was detected in the tumor tissue of anionic ML-injected animals ([Figure 5A](#F0005){ref-type="fig"}). A distinct blue color can be seen on the histological slices of the cRGD-MLs injected animals ([Figure 5B](#F0005){ref-type="fig"}) indicating the presence of iron particles. These MLs were noticed in the tumor region where also necrotic areas were visible ([Figure 5C](#F0005){ref-type="fig"}).Figure 5Hematoxylin and eosin stainings of tumors. Representative complete overviews of the histological sections of tumors derived from animals injected with either anionic magnetoliposomes (MLs) (**A**) or cRGD-MLs (**B**). (**C**) is an amplification of (**B**). The blue "dots" in the tumor, indicate the presence of Fe and are caused by the targeted uptake of cRGD-MLs. This signal is absent in the control tumors. Scale bar (**A, B**) =500 µm. Scale bar (**C**) =200 µm.

Discussion {#S0004}
==========

In this study, we generated cRGD-functionalized MLs for targeting newly formed blood vessels of tumors and tumor cells. We were able to monitor the uptake of these MLs by using in vivo MRI. This uptake was further assessed by in vivo and ex vivo FLI, EPR and histology. By functionalizing MLs with a cRGD peptide, we aimed at targeting the αvβ3 integrin. The αvβ3 was chosen as it is highly expressed on activated endothelial cells and newborn vessels, but it is absent on resting endothelial cells and most physiological tissues, making it a suitable target for tumor imaging.[@CIT0033]--[@CIT0035]

In vitro studies have shown that NPs of around 50 nm diameter are ideal in size for cellular interactions, while cell uptake of larger NPs is less efficient.[@CIT0036] To facilitate tumor uptake, we have synthesized particles with a HD of 53.5±0.3 and 57.8±3.7 nm for anionic and cRGD functionalized MLs, respectively. Our MLs presented a low PDI of 0.32±0.03 and a Z potential of -65.12±2.02mV, indicating an anionic charge of the MLs. Electrostatic interactions of these NPs with the cationic parts of the cell membrane contributes to their high cellular accumulation.[@CIT0036] Prior studies with anionic MLs demonstrated that these were taken up reaching an iron concentration of up to 18.9 pg Fe/cell.[@CIT0037]--[@CIT0039] These values are in agreement with previously reported levels of non-speciﬁc uptake of other iron oxide NPs by other cell types.[@CIT0040]--[@CIT0043]

To test the biocompatibility under in vitro conditions, the toxicity of the MLs was tested on the target cell line, a human ovarian cancer cell line (SKOV-3) showing a high expression of αvβ3 receptors, and a positive and negative control cell line, a mouse hepatic stellate cell line (GRX) and a human epithelial cell line (BEAS2B), respectively.[@CIT0044],[@CIT0045] By using these different cell lines, the specificity of active targeting was also assessed. We investigated optimal NP/cell interaction by labeling the different cell lines with anionic and cRGD-MLs at increasing concentrations (5--100 µg Fe/ml medium). No noticeable effect on cell viability, oxidative stress or cell morphology was observed in cells when labeled with cRGD-MLs or anionic MLS for 24 hrs, for any of the concentrations tested (up to 100 µg iron/ml medium).

In addition to the in vitro experiments, we evaluated the use of in vivo imaging modalities (MRI and FLI) to monitor intra-tumoral ML uptake. As expected, negative T2 MR contrast induced by the superparamagnetic iron oxide cores of the MLs increased (decrease of signal intensity) in the tumors within 4h after cRGD-ML injection. We observed an accentuated increase in MR contrast in the tumor tissue in cRGD-MLs injected mice in contrary to anionic-MLs injected animals. This indicates that the cRGD-MLs are accumulating in the tumors by an active targeting process and that passive accumulation by the EPR effect is not sufficient for non-functionalized (anionic) MLs for similarly high accumulation in the tumor.[@CIT0046],[@CIT0047] It is worth noting that we observed an overall increase in T2 values for the animals injected with anionic-MLs over-time, most likely due to increased edema, necrosis and overall heterogeneity of the tumor mass, leading to heterogeneities on T2-weighted MR images.[@CIT0048]

Similarly, increased uptake was observed on FLI images following administration of cRGD-MLs. We observed an increase in total radiant efficiency at the tumor site, immediately after the injection of the cRGD-MLs with a maximum uptake after 24h. The slight difference between the maximum uptake time point in MRI and FLI at 4h in contrast to 24h, respectively, can be explained because FLI and MRI measurements were performed on different groups of animal, adding inter-animal variability to the distribution profile of the MLs. Nevertheless, this did not interfere with the general findings that the overall uptake profile of cRGD and anionic MLs is different, indicating increased accumulation of cRGD-MLs in the tumors.

Even though MRI and FLI provided similar indications of cRGD-MLs uptake, FLI is less sensitive to early changes due to larger influences of background signal of circulating MLs, in particular in highly vascularized regions close to the surface (eg head and neck region). Furthermore, high baseline background signals might obscure uptake in other organs, like liver and spleen, as might be the case in the mice injected with anionic MLs. On the other hand, FLI is relatively easy to use, rapid and inexpensive in animal models, making it an effective screening tool for evaluation and comparison of vascular targeting. However, its application will be restricted by the limited depth penetration of light, biasing the intensity towards tumor surface and underestimating the signal changes at deeper regions of the xenograft.[@CIT0049]

For validation, mice were sacrificed 2, 4 and 48 hrs after injection of MLs following MRI or FLI, respectively. Tumors were resected and examined by ex vivo FLI and EPR spectroscopy. We found a significant increase in relative total radiant efficiency in FLI of tumors harvested two hours after injection. This discrepancy between ex vivo and in vivo FLI confirms that the latter is challenging when the maximum signal is more transient.[@CIT0050] Using EPR spectroscopy, the presence of Fe~3~O~4~ residues inside the tissues was confirmed. The total iron content in tumors of cRGD-ML injected mice increased 2h after injection, with a maximum uptake per mg of tumor tissue after 4h (1.26±0.30 ng Fe~3~O~4~/mg dry tissue) in comparison with anionic MLs (0.39±0.03 ng Fe~3~O~4~/mg dry tissue), confirming that the tumor cells preferentially took up the cRGD-MLs (ratio cRGD/anionic MLs of 2.03).

We have also noticed a greater accumulation of the cRGD-MLs in the spleen which might also contribute to this effect. It is known from the literature that approximately 80% of the injected dose of iron oxide nanoparticles is take up by Kupfer cells and 5--10% of the injected dose ends up in the spleen.[@CIT0051] Furthermore, macrophages are equipped with scavenger receptors recognizing charged molecules, such as the free maleimide groups in the cRGD-MLs formulation.[@CIT0052] This could increase the recognition of these nanoparticles by the macrophages and therefore, their uptake in the spleen, as it was also shown in other studies.[@CIT0053]

While the utilization of cRGD-nanoparticles to target tumor cells is not entirely new, previous studies have mostly focused on short-term follow-up (maximum 24h) of such NPs using a single modality, eg MRI or PET, with little to no ex vivo confirmation of NP-uptake in the tumors.[@CIT0054],[@CIT0055] In this study, we were able to demonstrate the suitability of cRGD-MLs as a diagnostic agent for combined multimodal imaging using MRI and FLI. By combining MRI and FLI in a dual-modality approach, MRI could provide high resolution, three-dimensional and quantitative information on cRGD-MLs uptake by the tumors, while FLI could provide rapid full body information on ML distribution and temporal changes. Furthermore, the great r~2~/r~1~ ratio achieved by the MLs in combination excellent biocompatibility makes them interesting candidates for future clinical studies.[@CIT0021],[@CIT0038] The good tolerance of cells towards MLs further enabled us to use relatively high iron concentrations without any adverse effects in vitro or in vivo. In future studies, these MLs can be used theranostic agents for the follow-up of anti-vascular therapies as they target tumor neovasculature.[@CIT0056]

Conclusion {#S0005}
==========

In conclusion, we were able to monitor the tumor-specific uptake of cRGD-MLs using MRI and FLI and confirm it by using EPR and histology. FLI, however, was less sensitive in detecting the RGD-MLs accumulation in vivo as it is limited by a low depth penetration and requires high local concentrations of NPs relative to background. On the other hand, T2-weighted MRI has its limitations due to potentially misleading changes in background signal (T2 values) caused by physiological changes (edema, hemorrhages etc.).
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Supplementary materials {#S0009}
=======================

Cyclic RGD peptide-labeled MLs synthesis {#S0009-S2001}
----------------------------------------

Small anionic MLs were produced as previously described \[30\]. In short, sonicated vesicles containing a mixture of 1,2-Dimyristoyl-sn-glycero-3-phosphorylcholine (DMPC) and 1,2-Dimyristoyl-sn-glycero-3-phosphorylglycerol sodium salt (DMPG) (both from Avanti Polar Lipids, Alabaster, Alabama) (9:1) in 2-\[Tris(hydroxymethyl)-methylamino\]-ethanesulfonic acid (TES) buffer (5 mM, pH 7.0; Sigma-Aldrich, Overijse, Belgium) were mixed at a lipid/Fe3O4 weight ratio of 1:5 with a water compatible magnetic fluid at room temperature (RT). Subsequently the mixture was dialyzed for 3 days against TES buffer with regular buffer changes. Separation of the resulting MLs from the excess vesicles was performed by high-gradient magnetophoresis (HGM) and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-polyethylene glycol-maleimide (DSPE-PEG-MAL, 2-5% mol) (Avanti Polar Lipids, Alabaster, Alabama) was added to the anionic vesicles. The RGD peptide was linked to the MLs formulation via a sulfhydryl group at the cysteine residue of the DSPE-PEG-MAL by overnight incubation at a 10:1 molar ratio (Supplementary Scheme 1). A custom-made cyclic RGD peptide, labeled with fluorescein isothiocyanate (FITC), from Pepscan B.V (Lelystad, The Netherlands) was used. Additionally, a fluorescent lipid conjugate 1,2-Dipalmitoyl-sn-glycero-3-phosphoethanolamine (DPPE)-Texas Red (Avanti Polar Lipidis, Alabaster, Alabama) (0.75% mol) was added to the outer lipid layer of the MLs. Unbound cyclic RGD peptide and DPPE-Texas Red were separated from the magnetic MLs fraction by HGM.

Characterization of cRGD-MLs {#S0009-S2002}
----------------------------

A JEOL 2100 transmission electron microscope (JEOL Ltd., Tokyo, Japan) working at 80 keV was used to image the nanostructures. Cryogen frozen samples were prepared in a FEI Vitrobot™ (Thermo Fischer Scientific) under the following parameters: Sample volume, 7.5 μl; Blot time, 3 s; Wait time, 1 s; Drain time, 0 s; Blot force, −3; Blot total, 1. Lacey carbon coated, 300 mesh, copper grids (Ted Pella, Redding, CA, USA) were used for the samples. Hydrodynamic size and surface charge studies were performed on a Horiba nanoPartica SZ-100 (Horiba Ltd., Kyoto, Japan) instrument directly in water solutions. Measurements were performed directly in water at 37 ºC in disposable cuvettes. Carbon electrodes were used for the zeta potential measurements. In both cases, results are shown as the average of four independent measurements ± standard deviation.

High-content image analysis for cell viability, mitochondrial ROS, and morphology {#S0009-S2003}
---------------------------------------------------------------------------------

To investigate the effect of following the exposure period, cells were washed twice with phosphate-buffered saline (PBS, Gibco Life Technologies) and were immediately fixed with 4% PFA to prepare for actin staining. Next, cells were permeabilized for 10 mins with Triton X-100 (1%, Sigma-Aldrich) and blocked for 30 min with 10% serum-containing PBS, followed by incubation with Acti-stain 488 phalloidin (TebuBio, Belgium) at RT. For samples reserved for viability, samples were fixed with 4% paraformaldehyde (PFA) and incubated with LIVE/DEAD^®^ Fixable Green Dead Cell Stain Kit (Thermo Fisher Scientific) for 30 min at 37°C and 5% CO2. Samples reserved for mitochondrial ROS studies, live cells were incubated at 37°C and 5% CO2 for 30 min with MitoTracker Red CMXRos (Molecular Probes, Life Technologies Europe, Belgium). Subsequently, all cells were washed twice with PBS and counterstained with 1:500 Hoechst (Thermo Fisher Scientific) for 10 min in the dark at RT. All samples were kept in PBS, in the dark at 4°C, until analyzed with the InCell Analyzer 2000 (GE Healthcare Europe GmbH, Belgium). Data processing was performed using Investigator Tool 1.6.1 (GE Healthcare Europe GmbH) software on which the cells were segmented and fluorescence intensities were determined in individual cells. Figure S1Schematic representation of RGD functionalized magnetoliposomes synthesis procedure. The RGD peptide was linked via a sulfhydryl (-SH) group of the cysteine in the cyclic-RGD peptide that couples to the maleimide groups at the distal end of the DSPE-PEG-MAL group. The liposome suspension was incubated with cyclic RGD peptide at a molar ratio of 10:1 overnight. Figure S2Experimental outline of the in vivo imaging experiments. Two separate groups of animals were used for the fluorescence imaging (FLI) and Magnetic Ressonance Imaging (MRI) experiments. Figure S3Representation of high content image analysis for (**A**) cell viability, (**B**) membrane damage, (**C**--**D**) cell morphology (cell size and skewness) and (**E**--**F**) mitochondrial ROS formation and stress levels for BEAS-2B, GRX and SKOV-3 cells labeled with increasing concentrations of anionic (AN) and cRGD-MLs for 24 h via color-coded heat maps. Data are presented as mean ± SD vs control. Acquired data were analyzed using two-way ANOVA. No significance difference was found after incubating the cells with either anionic or RGD-MLs.
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